8-K: Ingersoll Rand to Acquire ILC Dover for $2.325 Billion, Expanding Life Sciences Presence

Ingersoll Rand has agreed to acquire ILC Dover for $2.325 billion in cash, plus a potential earnout, to expand its presence in the life sciences sector.

Summary

• Ingersoll Rand has announced a definitive agreement to acquire ILC Dover from New Mountain Capital for an upfront cash payment of approximately $2.325 billion.
• The deal includes a potential earnout based on the achievement of certain operating efficiency metrics in 2024, which could increase the purchase multiple by less than one turn.
• ILC Dover is a leader in the design and production of solutions for biopharmaceutical, pharmaceutical, and medical device markets, with a 75-year history of innovation.
• The acquisition is expected to close in Q2 2024, subject to customary regulatory approvals.
• ILC Dover has approximately 2,000 employees and 11 engineering and production facilities across North America, Europe, and Asia.
• Ingersoll Rand will establish a life sciences platform within its Precision and Science Technologies (P&ST) segment, combining ILC with existing life science-focused brands.
• The new life sciences platform is expected to have approximately $700 million in revenue.
• ILC's revenue has grown at a mid-teens compound annual growth rate (CAGR) organically over the last three years and is expected to reach almost $400 million in 2024, with mid-30s Adjusted EBITDA margins.
• Ingersoll Rand expects to achieve a return on invested capital (ROIC) in the high single digits by year three of its ownership through the deployment of its operational excellence program and organic growth initiatives.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strategic acquisition, strong growth metrics of ILC Dover, and the expected financial benefits for Ingersoll Rand. The management commentary is also optimistic.

Positives

• The acquisition is immediately accretive to Ingersoll Rand's growth and margin rates.
• ILC Dover has a strong track record of organic revenue growth and high EBITDA margins.
• The acquisition expands Ingersoll Rand's presence in the high-growth life sciences market.
• ILC Dover has a high percentage of recurring revenue streams, approximately 75%.
• The deal provides access to approximately 1,000 new customers in the life science and healthcare sectors.
• The acquisition will enable Ingersoll Rand to leverage its existing technologies and demand generation capabilities.
• The combined life sciences platform will allow for a more comprehensive offering to customers.

Negatives

• The acquisition is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the deal from closing.
• There is a potential earnout payment, which could increase the total cost of the acquisition.
• The integration of ILC Dover into Ingersoll Rand's operations could present challenges.
• There are risks associated with achieving the expected synergies and financial performance from the acquisition.

Risks

• The acquisition is subject to regulatory approvals, which could delay or prevent the deal from closing.
• There are risks associated with integrating ILC Dover into Ingersoll Rand's operations.
• The company may not achieve the expected revenue and cost synergies from the acquisition.
• There are risks related to retaining key personnel from ILC Dover.
• The company is exposed to general economic and industry-specific risks.
• There are risks related to the uncertainty of the expected financial performance of the company.
• There are risks related to the ability of the company to implement its business strategy.

Future Outlook

Ingersoll Rand expects to achieve a high single-digit ROIC by year three of its ownership of ILC Dover. The company also anticipates leveraging ILC's market positions and brands to drive incremental growth in other Ingersoll Rand product lines.

Management Comments

• Vicente Reynal, Ingersoll Rand chairman and CEO, stated that this acquisition is the next phase of their long-term vision to expand into higher-growth end markets like life sciences.
• Vicente Reynal expressed excitement about partnering with Corey Walker and the ILC team.
• Corey Walker, ILC President and CEO, is excited to combine the Ingersoll Rand and ILC Life Science portfolio of products.
• Andre Moura, Managing Director at New Mountain Capital, stated that they see a strong fit between Ingersoll Rand and ILC.

Industry Context

This acquisition reflects a broader trend of companies seeking to expand their presence in the high-growth life sciences sector. The life sciences market is characterized by strong demand for innovative solutions and recurring revenue streams, making it an attractive area for investment.

Comparison to Industry Standards

• The 17x EBITDA multiple is within the range of recent acquisitions in the life sciences sector, but the specific multiple will depend on the growth rate and profitability of the target company.
• Comparable companies in the life sciences space include Danaher, Thermo Fisher Scientific, and Sartorius, which have all made acquisitions to expand their offerings.
• The mid-teens revenue growth rate of ILC Dover is strong compared to the overall industrial sector, but is not unusual for companies in the life sciences sector.
• The mid-30s EBITDA margins are also strong and are in line with other high-performing companies in the life sciences sector.

Management Changes

Stakeholder Impact

• Shareholders are expected to benefit from the accretive nature of the acquisition and the expansion into a high-growth market.
• Employees of both Ingersoll Rand and ILC Dover will be impacted by the integration of the two companies.
• Customers of both companies will have access to a broader range of products and services.
• Suppliers of both companies may see changes in their relationships.
• Creditors of both companies may be impacted by the financial implications of the acquisition.

Next Steps

• The acquisition is expected to close in Q2 2024, subject to regulatory approvals.
• Ingersoll Rand will establish a life sciences platform within its P&ST segment.
• The company will integrate ILC Dover into its operations and leverage its operational excellence program to drive synergies.
• Ingersoll Rand will host an investor conference call to discuss the acquisition.

Key Dates

Keywords

acquisition, life sciences, ILC Dover, Ingersoll Rand, merger, biopharma, pharma, medical devices, EBITDA, revenue, growth, ROIC